smscall
logo
Pharma & Healthcare

Published On: Feb 6, 2025

Global Viral Vaccines Market Outlook and Growth Opportunities 2025

  • starstarstarstarstar
  • 0
  • 0 Reviews
  • 199 Pages
  • 0 Views

Version Type

$4,250.00

Summary
According to APO Research, the global Viral Vaccines market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Viral Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Viral Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Viral Vaccines market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Viral Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Viral Vaccines market include GSK, Sanofi, Novartis, Merck, Pfizer, Bayer, Zoetis, Johnson and CSL, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Viral Vaccines, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Viral Vaccines, also provides the sales of main regions and countries. Of the upcoming market potential for Viral Vaccines, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Viral Vaccines sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Viral Vaccines market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Viral Vaccines sales, projected growth trends, production technology, application and end-user industry.
Viral Vaccines Segment by Company
GSK
Sanofi
Novartis
Merck
Pfizer
Bayer
Zoetis
Johnson
CSL
AstraZeneca
Viral Vaccines Segment by Type
Attenuated Vaccine
Inactivated Vaccine
Viral Vaccines Segment by Application
Research Institute
Hospital
Pharmaceutical Factory
Others
Viral Vaccines Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Viral Vaccines status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Viral Vaccines market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Viral Vaccines significant trends, drivers, influence factors in global and regions.
6. To analyze Viral Vaccines competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Viral Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Viral Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Viral Vaccines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Viral Vaccines market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Viral Vaccines industry.
Chapter 3: Detailed analysis of Viral Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Viral Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Viral Vaccines in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Table 1:Viral Vaccines Industry Trends
Table 2:Viral Vaccines Industry Drivers
Table 3:Viral Vaccines Industry Opportunities and Challenges
Table 4:Viral Vaccines Industry Restraints
Table 5:Global Viral Vaccines Revenue by Company (US$ Million) & (2020-2025)
Table 6:Global Viral Vaccines Revenue Share by Company (2020-2025)
Table 7:Global Viral Vaccines Sales Volume by Company (W Tons) & (2020-2025)
Table 8:Global Viral Vaccines Sales Volume Share by Company (2020-2025)
Table 9:Global Viral Vaccines Average Price (US$/Ton) of Company (2020-2025)
Table 10:Global Viral Vaccines Company Ranking, (2023-2025) & (USD Million)
Table 11:Global Viral Vaccines Key Company Manufacturing Base & Headquarters
Table 12:Global Viral Vaccines Company, Product Type & Application
Table 13:Global Viral Vaccines Company Establishment Date
Table 14:Global Company Market Concentration Ratio (CR5 and HHI)
Table 15:Global Viral Vaccines by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2024)
Table 16:Mergers & Acquisitions, Expansion
Table 17:Significant Companies of Attenuated Vaccine
Table 18:Significant Companies of Inactivated Vaccine
Table 19:Global Viral Vaccines Sales Volume by Type 2020 VS 2024 VS 2031 (W Tons)
Table 20:Global Viral Vaccines Sales Volume by Type (2020-2025) & (W Tons)
Table 21:Global Viral Vaccines Sales Volume by Type (2026-2031) & (W Tons)
Table 22:Global Viral Vaccines Sales Volume Share by Type (2020-2025)
Table 23:Global Viral Vaccines Sales Volume Share by Type (2026-2031)
Table 24:Global Viral Vaccines Sales Value by Type 2020 VS 2024 VS 2031 (US$ Million)
Table 25:Global Viral Vaccines Sales Value by Type (2020-2025) & (US$ Million)
Table 26:Global Viral Vaccines Sales Value by Type (2026-2031) & (US$ Million)
Table 27:Global Viral Vaccines Sales Value Share by Type (2020-2025)
Table 28:Global Viral Vaccines Sales Value Share by Type (2026-2031)
Table 29:Significant Companies of Research Institute
Table 30:Significant Companies of Hospital
Table 31:Significant Companies of Pharmaceutical Factory
Table 32:Significant Companies of Others
Table 33:Global Viral Vaccines Sales Volume by Application 2020 VS 2024 VS 2031 (W Tons)
Table 34:Global Viral Vaccines Sales Volume by Application (2020-2025) & (W Tons)
Table 35:Global Viral Vaccines Sales Volume by Application (2026-2031) & (W Tons)
Table 36:Global Viral Vaccines Sales Volume Share by Application (2020-2025)
Table 37:Global Viral Vaccines Sales Volume Share by Application (2026-2031)
Table 38:Global Viral Vaccines Sales Value by Application 2020 VS 2024 VS 2031 (US$ Million)
Table 39:Global Viral Vaccines Sales Value by Application (2020-2025) & (US$ Million)
Table 40:Global Viral Vaccines Sales Value by Application (2026-2031) & (US$ Million)
Table 41:Global Viral Vaccines Sales Value Share by Application (2020-2025)
Table 42:Global Viral Vaccines Sales Value Share by Application (2026-2031)
Table 43:Global Viral Vaccines Sales by Region: 2020 VS 2024 VS 2031 (W Tons)
Table 44:Global Viral Vaccines Sales by Region (2020-2025) & (W Tons)
Table 45:Global Viral Vaccines Sales Market Share by Region (2020-2025)
Table 46:Global Viral Vaccines Sales by Region (2026-2031) & (W Tons)
Table 47:Global Viral Vaccines Sales Market Share by Region (2026-2031)
Table 48:Global Viral Vaccines Sales Value Comparison by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 49:Global Viral Vaccines Sales Value by Region (2020-2025) & (US$ Million)
Table 50:Global Viral Vaccines Sales Value Share by Region (2020-2025)
Table 51:Global Viral Vaccines Sales Value by Region (2026-2031) & (US$ Million)
Table 52:Global Viral Vaccines Sales Value Share by Region (2026-2031)
Table 53:Global Viral Vaccines Market Average Price (US$/Ton) by Region (2020-2025)
Table 54:Global Viral Vaccines Market Average Price (US$/Ton) by Region (2026-2031)
Table 55:Global Viral Vaccines Sales by Country: 2020 VS 2024 VS 2031 (W Tons)
Table 56:Global Viral Vaccines Sales Value by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 57:Global Viral Vaccines Sales by Country (2020-2025) & (W Tons)
Table 58:Global Viral Vaccines Sales Market Share by Country (2020-2025)
Table 59:Global Viral Vaccines Sales by Country (2026-2031) & (W Tons)
Table 60:Global Viral Vaccines Sales Market Share by Country (2026-2031)
Table 61:Global Viral Vaccines Sales Value by Country (2020-2025) & (US$ Million)
Table 62:Global Viral Vaccines Sales Value Market Share by Country (2020-2025)
Table 63:Global Viral Vaccines Sales Value by Country (2026-2031) & (US$ Million)
Table 64:Global Viral Vaccines Sales Value Market Share by Country (2026-2031)
Table 65:GSK Company Information
Table 66:GSK Business Overview
Table 67:GSK Viral Vaccines Sales (W Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 68:GSK Viral Vaccines Product Portfolio
Table 69:GSK Recent Development
Table 70:Sanofi Company Information
Table 71:Sanofi Business Overview
Table 72:Sanofi Viral Vaccines Sales (W Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 73:Sanofi Viral Vaccines Product Portfolio
Table 74:Sanofi Recent Development
Table 75:Novartis Company Information
Table 76:Novartis Business Overview
Table 77:Novartis Viral Vaccines Sales (W Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 78:Novartis Viral Vaccines Product Portfolio
Table 79:Novartis Recent Development
Table 80:Merck Company Information
Table 81:Merck Business Overview
Table 82:Merck Viral Vaccines Sales (W Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 83:Merck Viral Vaccines Product Portfolio
Table 84:Merck Recent Development
Table 85:Pfizer Company Information
Table 86:Pfizer Business Overview
Table 87:Pfizer Viral Vaccines Sales (W Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 88:Pfizer Viral Vaccines Product Portfolio
Table 89:Pfizer Recent Development
Table 90:Bayer Company Information
Table 91:Bayer Business Overview
Table 92:Bayer Viral Vaccines Sales (W Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 93:Bayer Viral Vaccines Product Portfolio
Table 94:Bayer Recent Development
Table 95:Zoetis Company Information
Table 96:Zoetis Business Overview
Table 97:Zoetis Viral Vaccines Sales (W Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 98:Zoetis Viral Vaccines Product Portfolio
Table 99:Zoetis Recent Development
Table 100:Johnson Company Information
Table 101:Johnson Business Overview
Table 102:Johnson Viral Vaccines Sales (W Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 103:Johnson Viral Vaccines Product Portfolio
Table 104:Johnson Recent Development
Table 105:CSL Company Information
Table 106:CSL Business Overview
Table 107:CSL Viral Vaccines Sales (W Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 108:CSL Viral Vaccines Product Portfolio
Table 109:CSL Recent Development
Table 110:AstraZeneca Company Information
Table 111:AstraZeneca Business Overview
Table 112:AstraZeneca Viral Vaccines Sales (W Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 113:AstraZeneca Viral Vaccines Product Portfolio
Table 114:AstraZeneca Recent Development
Table 115:Key Raw Materials
Table 116:Raw Materials Key Suppliers
Table 117:Viral Vaccines Distributors List
Table 118:Viral Vaccines Customers List
Table 119:Research Programs/Design for This Report
Table 120:Authors List of This Report
Table 121:Secondary Sources
Table 122:Primary Sources
Figure 1:Viral Vaccines Product Image
Figure 2:Global Viral Vaccines Sales Value (US$ Million), 2020 VS 2024 VS 2031
Figure 3:Global Viral Vaccines Sales Value (2020-2031) & (US$ Million)
Figure 4:Global Viral Vaccines Sales (2020-2031) & (W Tons)
Figure 5:Global Viral Vaccines Sales Average Price (US$/Ton) & (2020-2031)
Figure 6:Global Viral Vaccines Company Revenue Ranking in 2024 (US$ Million)
Figure 7:Global Top 5 and 10 Company Market Share by Revenue in 2024 (US$ Million)
Figure 8:Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 9:Attenuated Vaccine Image
Figure 10:Inactivated Vaccine Image
Figure 11:Global Viral Vaccines Sales Volume by Type (2020 VS 2024 VS 2031) & (W Tons)
Figure 12:Global Viral Vaccines Sales Volume Share 2020 VS 2024 VS 2031
Figure 13:Global Viral Vaccines Sales Volume Share by Type (2020-2031)
Figure 14:Global Viral Vaccines Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
Figure 15:Global Viral Vaccines Sales Value Share 2020 VS 2024 VS 2031
Figure 16:Global Viral Vaccines Sales Value Share by Type (2020-2031)
Figure 17:Research Institute Image
Figure 18:Hospital Image
Figure 19:Pharmaceutical Factory Image
Figure 20:Others Image
Figure 21:Global Viral Vaccines Sales Volume by Application (2020 VS 2024 VS 2031) & (W Tons)
Figure 22:Global Viral Vaccines Sales Volume Share 2020 VS 2024 VS 2031
Figure 23:Global Viral Vaccines Sales Volume Share by Application (2020-2031)
Figure 24:Global Viral Vaccines Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
Figure 25:Global Viral Vaccines Sales Value Share 2020 VS 2024 VS 2031
Figure 26:Global Viral Vaccines Sales Value Share by Application (2020-2031)
Figure 27:Global Viral Vaccines Sales by Region: 2020 VS 2024 VS 2031 (W Tons)
Figure 28:Global Viral Vaccines Sales Market Share by Region: 2020 VS 2024 VS 2031
Figure 29:Global Viral Vaccines Sales Value Comparison by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 30:Global Viral Vaccines Sales Value Share by Region: 2020 VS 2024 VS 2031
Figure 31:North America Viral Vaccines Sales Value (2020-2031) & (US$ Million)
Figure 32:North America Viral Vaccines Sales Value Share by Country (%), 2024 VS 2031
Figure 33:Europe Viral Vaccines Sales Value (2020-2031) & (US$ Million)
Figure 34:Europe Viral Vaccines Sales Value Share by Country (%), 2024 VS 2031
Figure 35:Asia-Pacific Viral Vaccines Sales Value (2020-2031) & (US$ Million)
Figure 36:Asia-Pacific Viral Vaccines Sales Value Share by Country (%), 2024 VS 2031
Figure 37:South America Viral Vaccines Sales Value (2020-2031) & (US$ Million)
Figure 38:South America Viral Vaccines Sales Value Share by Country (%), 2024 VS 2031
Figure 39:Middle East & Africa Viral Vaccines Sales Value (2020-2031) & (US$ Million)
Figure 40:Middle East & Africa Viral Vaccines Sales Value Share by Country (%), 2024 VS 2031
Figure 41:USA Viral Vaccines Sales Value Growth Rate (2020-2031) & (US$ Million)
Figure 42:USA Viral Vaccines Sales Value Share by Type, 2024 VS 2031 & (%)
Figure 43:USA Viral Vaccines Sales Value Share by Application, 2024 VS 2031 & (%)
Figure 44:Canada Viral Vaccines Sales Value Growth Rate (2020-2031) & (US$ Million)
Figure 45:Canada Viral Vaccines Sales Value Share by Type, 2024 VS 2031 & (%)
Figure 46:Canada Viral Vaccines Sales Value Share by Application, 2024 VS 2031 & (%)
Figure 47:Mexico Viral Vaccines Sales Value Growth Rate (2020-2031) & (US$ Million)
Figure 48:Mexico Viral Vaccines Sales Value Share by Type, 2024 VS 2031 & (%)
Figure 49:Mexico Viral Vaccines Sales Value Share by Application, 2024 VS 2031 & (%)
Figure 50:Germany Viral Vaccines Sales Value Growth Rate (2020-2031) & (US$ Million)
Figure 51:Germany Viral Vaccines Sales Value Share by Type, 2024 VS 2031 & (%)
Figure 52:Germany Viral Vaccines Sales Value Share by Application, 2024 VS 2031 & (%)
Figure 53:France Viral Vaccines Sales Value Growth Rate (2020-2031) & (US$ Million)
Figure 54:France Viral Vaccines Sales Value Share by Type, 2024 VS 2031 & (%)
Figure 55:France Viral Vaccines Sales Value Share by Application, 2024 VS 2031 & (%)
Figure 56:U.K. Viral Vaccines Sales Value Growth Rate (2020-2031) & (US$ Million)
Figure 57:U.K. Viral Vaccines Sales Value Share by Type, 2024 VS 2031 & (%)
Figure 58:U.K. Viral Vaccines Sales Value Share by Application, 2024 VS 2031 & (%)
Figure 59:Italy Viral Vaccines Sales Value Growth Rate (2020-2031) & (US$ Million)
Figure 60:Italy Viral Vaccines Sales Value Share by Type, 2024 VS 2031 & (%)
Figure 61:Italy Viral Vaccines Sales Value Share by Application, 2024 VS 2031 & (%)
Figure 62:Spain Viral Vaccines Sales Value Growth Rate (2020-2031) & (US$ Million)
Figure 63:Spain Viral Vaccines Sales Value Share by Type, 2024 VS 2031 & (%)
Figure 64:Spain Viral Vaccines Sales Value Share by Application, 2024 VS 2031 & (%)
Figure 65:Russia Viral Vaccines Sales Value Growth Rate (2020-2031) & (US$ Million)
Figure 66:Russia Viral Vaccines Sales Value Share by Type, 2024 VS 2031 & (%)
Figure 67:Russia Viral Vaccines Sales Value Share by Application, 2024 VS 2031 & (%)
Figure 68:Netherlands Viral Vaccines Sales Value Growth Rate (2020-2031) & (US$ Million)
Figure 69:Netherlands Viral Vaccines Sales Value Share by Type, 2024 VS 2031 & (%)
Figure 70:Netherlands Viral Vaccines Sales Value Share by Application, 2024 VS 2031 & (%)
Figure 71:Nordic Countries Viral Vaccines Sales Value Growth Rate (2020-2031) & (US$ Million)
Figure 72:Nordic Countries Viral Vaccines Sales Value Share by Type, 2024 VS 2031 & (%)
Figure 73:Nordic Countries Viral Vaccines Sales Value Share by Application, 2024 VS 2031 & (%)
Figure 74:China Viral Vaccines Sales Value Growth Rate (2020-2031) & (US$ Million)
Figure 75:China Viral Vaccines Sales Value Share by Type, 2024 VS 2031 & (%)
Figure 76:China Viral Vaccines Sales Value Share by Application, 2024 VS 2031 & (%)
Figure 77:Japan Viral Vaccines Sales Value Growth Rate (2020-2031) & (US$ Million)
Figure 78:Japan Viral Vaccines Sales Value Share by Type, 2024 VS 2031 & (%)
Figure 79:Japan Viral Vaccines Sales Value Share by Application, 2024 VS 2031 & (%)
Figure 80:South Korea Viral Vaccines Sales Value Growth Rate (2020-2031) & (US$ Million)
Figure 81:South Korea Viral Vaccines Sales Value Share by Type, 2024 VS 2031 & (%)
Figure 82:South Korea Viral Vaccines Sales Value Share by Application, 2024 VS 2031 & (%)
Figure 83:India Viral Vaccines Sales Value Growth Rate (2020-2031) & (US$ Million)
Figure 84:India Viral Vaccines Sales Value Share by Type, 2024 VS 2031 & (%)
Figure 85:India Viral Vaccines Sales Value Share by Application, 2024 VS 2031 & (%)
Figure 86:Australia Viral Vaccines Sales Value Growth Rate (2020-2031) & (US$ Million)
Figure 87:Australia Viral Vaccines Sales Value Share by Type, 2024 VS 2031 & (%)
Figure 88:Australia Viral Vaccines Sales Value Share by Application, 2024 VS 2031 & (%)
Figure 89:Southeast Asia Viral Vaccines Sales Value Growth Rate (2020-2031) & (US$ Million)
Figure 90:Southeast Asia Viral Vaccines Sales Value Share by Type, 2024 VS 2031 & (%)
Figure 91:Southeast Asia Viral Vaccines Sales Value Share by Application, 2024 VS 2031 & (%)
Figure 92:Brazil Viral Vaccines Sales Value Growth Rate (2020-2031) & (US$ Million)
Figure 93:Brazil Viral Vaccines Sales Value Share by Type, 2024 VS 2031 & (%)
Figure 94:Brazil Viral Vaccines Sales Value Share by Application, 2024 VS 2031 & (%)
Figure 95:Argentina Viral Vaccines Sales Value Growth Rate (2020-2031) & (US$ Million)
Figure 96:Argentina Viral Vaccines Sales Value Share by Type, 2024 VS 2031 & (%)
Figure 97:Argentina Viral Vaccines Sales Value Share by Application, 2024 VS 2031 & (%)
Figure 98:Chile Viral Vaccines Sales Value Growth Rate (2020-2031) & (US$ Million)
Figure 99:Chile Viral Vaccines Sales Value Share by Type, 2024 VS 2031 & (%)
Figure 100:Chile Viral Vaccines Sales Value Share by Application, 2024 VS 2031 & (%)
Figure 101:Colombia Viral Vaccines Sales Value Growth Rate (2020-2031) & (US$ Million)
Figure 102:Colombia Viral Vaccines Sales Value Share by Type, 2024 VS 2031 & (%)
Figure 103:Colombia Viral Vaccines Sales Value Share by Application, 2024 VS 2031 & (%)
Figure 104:Peru Viral Vaccines Sales Value Growth Rate (2020-2031) & (US$ Million)
Figure 105:Peru Viral Vaccines Sales Value Share by Type, 2024 VS 2031 & (%)
Figure 106:Peru Viral Vaccines Sales Value Share by Application, 2024 VS 2031 & (%)
Figure 107:Saudi Arabia Viral Vaccines Sales Value Growth Rate (2020-2031) & (US$ Million)
Figure 108:Saudi Arabia Viral Vaccines Sales Value Share by Type, 2024 VS 2031 & (%)
Figure 109:Saudi Arabia Viral Vaccines Sales Value Share by Application, 2024 VS 2031 & (%)
Figure 110:Israel Viral Vaccines Sales Value Growth Rate (2020-2031) & (US$ Million)
Figure 111:Israel Arabia Viral Vaccines Sales Value Share by Type, 2024 VS 2031 & (%)
Figure 112:Israel Arabia Viral Vaccines Sales Value Share by Application, 2024 VS 2031 & (%)
Figure 113:UAE Viral Vaccines Sales Value Growth Rate (2020-2031) & (US$ Million)
Figure 114:UAE Viral Vaccines Sales Value Share by Type, 2024 VS 2031 & (%)
Figure 115:UAE Viral Vaccines Sales Value Share by Application, 2024 VS 2031 & (%)
Figure 116:Turkey Viral Vaccines Sales Value Growth Rate (2020-2031) & (US$ Million)
Figure 117:Turkey Viral Vaccines Sales Value Share by Type, 2024 VS 2031 & (%)
Figure 118:Turkey Viral Vaccines Sales Value Share by Application, 2024 VS 2031 & (%)
Figure 119:Iran Viral Vaccines Sales Value Growth Rate (2020-2031) & (US$ Million)
Figure 120:Iran Viral Vaccines Sales Value Share by Type, 2024 VS 2031 & (%)
Figure 121:Iran Viral Vaccines Sales Value Share by Application, 2024 VS 2031 & (%)
Figure 122:Egypt Viral Vaccines Sales Value Growth Rate (2020-2031) & (US$ Million)
Figure 123:Egypt Viral Vaccines Sales Value Share by Type, 2024 VS 2031 & (%)
Figure 124:Egypt Viral Vaccines Sales Value Share by Application, 2024 VS 2031 & (%)
Figure 125:Viral Vaccines Value Chain
Figure 126:Manufacturing Cost Structure
Figure 127:Viral Vaccines Sales Mode & Process
Figure 128:Direct Comparison with Distribution Share
Figure 129:Distributors Profiles
Figure 130:Years Considered
Figure 131:Research Process
Figure 132:Key Executives Interviewed

Request a Sample

Sample excerpt is intended to facilitate an informed purchase decision. Its purpose is not to offer free information or act as a substitute for the comprehensive product. In order to tailor the sample to your specific requirements, we will reach out to you to gather more details about your criteria.

Report Cover

Pharma & Healthcare

Global Viral Vaccines Market Outlook and Growth Opportunities 2025

0| 0 Reviews

Pages: 199

Complete Your Request

Select Country
Phone

Customer reviews

  • starstarstarstarstar
  • 0 out of 5
  • 0 Reviews

5

star rating

4

star rating

3

star rating

2

star rating

1

star rating

No Rating Review Exist.

Write Review
  • starstarstarstarstar

Suggested Report

View More

No data found.